Meet the Minds Behind the Mission

A dedicated team of experts driving the battle against cancer, fueled by a passion for innovation and a profound commitment to improve patient's care.

PEPKON TEAM

Jonathan LEVY
Jonathan LEVY
Chief Executive Officer
A PharmD and ESSEC graduate with expertise in pharma development and business strategy. He worked at Abbott, Roche, and Juvisé, focusing on M&A and market access, mainly in oncology. He then joined Truffle Capital as a VC analyst, contributing to biotech investments, company creations and portfolio support.
Read more
Jonathan LEVY
Jonathan LEVY
Chief Executive Officer
Access to PepKon's LinkedIn profils

A PharmD and ESSEC graduate with expertise in pharma development and business strategy. He worked at Abbott, Roche, and Juvisé, focusing on M&A and market access, mainly in oncology. He then joined Truffle Capital as a VC analyst, contributing to biotech investments, company creations and portfolio support.

Philippe KAROYAN ​
Philippe KAROYAN ​
Co-founder, SAB Chairman
Philippe Karoyan, Professor at the Laboratoire de Biomolécules (Sorbonne Université, CNRS, ENS) and Head of DRUGLab, is an expert in therapeutic peptides with 6 related patents, including those for PepKon. His research focuses on innovative cancer peptide therapies.
Read more
Philippe KAROYAN ​
Philippe KAROYAN ​
Co-founder, SAB Chairman
Access to PepKon's LinkedIn profils

Philippe Karoyan, Professor at the Laboratoire de Biomolécules (Sorbonne Université, CNRS, ENS) and Head of DRUGLab, is an expert in therapeutic peptides with 6 related patents, including those for PepKon. His research focuses on innovative cancer peptide therapies.

Sterenn GOUBIN
Sterenn GOUBIN
Preclinical Project Manager
A Doctor of Veterinary Medicine, she gained expertise in preclinical research at CROs (CIT, MDS, Porsolt), serving as Study Director, Technical Operations Manager, and Animal Welfare & AAALAC Accreditation Manager. She then oversaw preclinical development at Alizé Pharma, a biotech specializing in cancer and type 2 diabetes therapeutics. In 2024, she joined Pepkon as a Preclinical Project Manager.
Read more
Sterenn GOUBIN
Sterenn GOUBIN
Preclinical Project Manager
Access to PepKon's LinkedIn profils

A Doctor of Veterinary Medicine, she gained expertise in preclinical research at CROs (CIT, MDS, Porsolt), serving as Study Director, Technical Operations Manager, and Animal Welfare & AAALAC Accreditation Manager. She then oversaw preclinical development at Alizé Pharma, a biotech specializing in cancer and type 2 diabetes therapeutics. In 2024, she joined Pepkon as a Preclinical Project Manager.

Luis GÒMEZ-MORALES
Luis GÒMEZ-MORALES
Scientific Project Manager​​
With a dual PhD from Universidad Autónoma de Nuevo León and Sorbonne Université, he began researching cancer biology in 2017. At Sorbonne, he gained expertise in peptide design under Philippe Karoyan. In 2022, he joined PepKon and is now Scientific Project Manager.
Read more
Luis GÒMEZ-MORALES
Luis GÒMEZ-MORALES
Scientific Project Manager​​
Access to PepKon's LinkedIn profils

With a dual PhD from Universidad Autónoma de Nuevo León and Sorbonne Université, he began researching cancer biology in 2017. At Sorbonne, he gained expertise in peptide design under Philippe Karoyan. In 2022, he joined PepKon and is now Scientific Project Manager.

Farah DOGHMANE
Farah DOGHMANE
Strategy & Innovation Project Manager
With a master's in biochemistry and molecular biology, specializing in medicinal chemistry and pharmacology, she is currently pursuing a doctorate in pharmacy. Farah began her career at Institut Curie as a biochemist engineer, studying protein interactions in metastatic cell motility. She then worked as a consultant at Deloitte before joining PepKon as Project Manager in Strategy & Innovation.
Read more
Farah DOGHMANE
Farah DOGHMANE
Strategy & Innovation Project Manager
Access to PepKon's LinkedIn profils

With a master's in biochemistry and molecular biology, specializing in medicinal chemistry and pharmacology, she is currently pursuing a doctorate in pharmacy. Farah began her career at Institut Curie as a biochemist engineer, studying protein interactions in metastatic cell motility. She then worked as a consultant at Deloitte before joining PepKon as Project Manager in Strategy & Innovation.

Natasha DANDA
Natasha DANDA
Research Engineer
With a Master’s degree in Molecular Genetics, Natasha gained experience at VIB, the University of Groningen, KU Leuven, and ICM as a Lab Manager or Research Assistant. A specialist in molecular and cellular biology applied to cancer, she is now a Research Engineer at PepKon, focusing on the cellular study of peptides.
Read more
Natasha DANDA
Natasha DANDA
Research Engineer
Access to PepKon's LinkedIn profils

With a Master’s degree in Molecular Genetics, Natasha gained experience at VIB, the University of Groningen, KU Leuven, and ICM as a Lab Manager or Research Assistant. A specialist in molecular and cellular biology applied to cancer, she is now a Research Engineer at PepKon, focusing on the cellular study of peptides.

Xavier ROUCHON
Xavier ROUCHON
Research Engineer
Holder of a Master’s degree from Paul Sabatier University in Toulouse, he is pursuing a career as a biotechnology engineer. Xavier gained extensive expertise in 3D cell culture and stem cell differentiation, with a strong focus on flow cytometry analysis, during his time at Treefrog Therapeutics. Now a Research Engineer at Pepkon, he evaluates peptide potency and the synergy potential of therapeutic leads.
Read more
Xavier ROUCHON
Xavier ROUCHON
Research Engineer
Access to PepKon's LinkedIn profils

Holder of a Master’s degree from Paul Sabatier University in Toulouse, he is pursuing a career as a biotechnology engineer. Xavier gained extensive expertise in 3D cell culture and stem cell differentiation, with a strong focus on flow cytometry analysis, during his time at Treefrog Therapeutics. Now a Research Engineer at Pepkon, he evaluates peptide potency and the synergy potential of therapeutic leads.

Olivia SOUFFLET
Olivia SOUFFLET
CIFRE Doctoral Thesis
Chemical engineer specialized in analytical and biological chemistry (Chimie ParisTech), Olivia is pursuing a PhD (CIFRE) at PepKon and Sorbonne Université, focusing on optimizing PepKon's proprietary peptides. With expertise in peptide synthesis, purification, and analysis, she previously worked on therapeutic peptide development at X-Pharma.
Read more
Olivia SOUFFLET
Olivia SOUFFLET
CIFRE Doctoral Thesis
Access to PepKon's LinkedIn profils

Chemical engineer specialized in analytical and biological chemistry (Chimie ParisTech), Olivia is pursuing a PhD (CIFRE) at PepKon and Sorbonne Université, focusing on optimizing PepKon's proprietary peptides. With expertise in peptide synthesis, purification, and analysis, she previously worked on therapeutic peptide development at X-Pharma.

Estefania ELIZALDI
Estefania ELIZALDI
MD & Master's in Management (apprenticeship)
Medical Doctor with a Master’s in Molecular and Cellular Biotherapies, Estefania is currently pursuing a Master’s in Management of Health Industries. As an apprenticeship student at PepKon, she contributes to the intersection of science and business. With international experience in Mexico, the U.S., and France, she brings a global perspective on medical needs and practices.
Read more
Estefania ELIZALDI
Estefania ELIZALDI
MD & Master's in Management (apprenticeship)
Access to PepKon's LinkedIn profils

Medical Doctor with a Master’s in Molecular and Cellular Biotherapies, Estefania is currently pursuing a Master’s in Management of Health Industries. As an apprenticeship student at PepKon, she contributes to the intersection of science and business. With international experience in Mexico, the U.S., and France, she brings a global perspective on medical needs and practices.

Consultants & advisors

Bonabes DE ROUGÉ
Bonabes DE ROUGÉ
Preclinical Advisor​
With a PhD from the Faculté de Médecine de Paris, he has 30 years of experience in drug and cosmetic development. He led Cellpep/Ambrilia as CEO/CSO and was COO and CEO at Peptigroupe Inc. Now, as Preclinical Development Advisor at PepKon, he brings expertise in preclinical drug development
Read more
Bonabes DE ROUGÉ
Bonabes DE ROUGÉ
Preclinical Advisor​
Access to PepKon's LinkedIn profils

With a PhD from the Faculté de Médecine de Paris, he has 30 years of experience in drug and cosmetic development. He led Cellpep/Ambrilia as CEO/CSO and was COO and CEO at Peptigroupe Inc. Now, as Preclinical Development Advisor at PepKon, he brings expertise in preclinical drug development

Amel HADRI
Amel HADRI
CMC Development Advisor​
With 23 years of experience in the pharmaceutical industry, she has held key positions such as CDMO Site Director, Pharma Development Consultant, COO, and Auditor of pharma and lab sites. As the founder of Inits, she established a consultancy specializing in pharmaceutical development, offering expert guidance to biotech and pharma companies. Amel supports PepKon in the CMC (Chemistry, Manufacturing, and Controls) domain.
Read more
Amel HADRI
Amel HADRI
CMC Development Advisor​
Access to PepKon's LinkedIn profils

With 23 years of experience in the pharmaceutical industry, she has held key positions such as CDMO Site Director, Pharma Development Consultant, COO, and Auditor of pharma and lab sites. As the founder of Inits, she established a consultancy specializing in pharmaceutical development, offering expert guidance to biotech and pharma companies. Amel supports PepKon in the CMC (Chemistry, Manufacturing, and Controls) domain.

Marina ICHÉ
Marina ICHÉ
Clinical Advisor​
A graduate of the Faculty of Pharmacy of Montpellier, she held roles in pharmaceutical labs and CROs, managed a biotech portfolio for a private fund, and founded ILife Consulting, a European CRO. She supports PepKon’s clinical plan optimization.
Read more
Marina ICHÉ
Marina ICHÉ
Clinical Advisor​
Access to PepKon's LinkedIn profils

A graduate of the Faculty of Pharmacy of Montpellier, she held roles in pharmaceutical labs and CROs, managed a biotech portfolio for a private fund, and founded ILife Consulting, a European CRO. She supports PepKon’s clinical plan optimization.

Jean-Paul BRIFFAUX
Jean-Paul BRIFFAUX
Non-Clinical Safety Advisor
With a Doctorate of Veterinary Medicine and a Ph.D. in Physiology, he is a seasoned toxicologist and former President of the French Society of Toxicology. He has extensive CRO experience, contributed to drug and vaccine approvals, and chaired the Animal Ethics Committee. Since 2020, he is a Toxiclogy Expert.
Read more
Jean-Paul BRIFFAUX
Jean-Paul BRIFFAUX
Non-Clinical Safety Advisor
Access to PepKon's LinkedIn profils

With a Doctorate of Veterinary Medicine and a Ph.D. in Physiology, he is a seasoned toxicologist and former President of the French Society of Toxicology. He has extensive CRO experience, contributed to drug and vaccine approvals, and chaired the Animal Ethics Committee. Since 2020, he is a Toxiclogy Expert.

Claire VERSCHELDE
Claire VERSCHELDE
Intellectual Property Advisor​
She holds an MSc in Molecular and Cellular Biology and a PhD in Immunology. After starting at Cabinet Plasseraud in Biotech, she co-founded ICOSA specializing in Biotech IP. As a European Patent Attorney, she manages patent portfolios and advises on IP strategy. Claire supports PepKon's IP strategy.
Read more
Claire VERSCHELDE
Claire VERSCHELDE
Intellectual Property Advisor​
Access to PepKon's LinkedIn profils

She holds an MSc in Molecular and Cellular Biology and a PhD in Immunology. After starting at Cabinet Plasseraud in Biotech, she co-founded ICOSA specializing in Biotech IP. As a European Patent Attorney, she manages patent portfolios and advises on IP strategy. Claire supports PepKon's IP strategy.

Board of directors

Florence ALLOUCHE AKNIN
Florence ALLOUCHE AKNIN
Chairman of the Board
She is a PharmD and MBA graduate of HEC Paris with experience as a hospital pharmacist and in the pharma industry. She founded the APHP Technology Transfer Office, creating over 75 health startups. She co-founded SparingVision and raised €130M. Now, she chairs PepKon’s Executive Committee and advises on R&D strategy.
Read more
Florence ALLOUCHE AKNIN
Florence ALLOUCHE AKNIN
Chairman of the Board
Access to PepKon's LinkedIn profils

She is a PharmD and MBA graduate of HEC Paris with experience as a hospital pharmacist and in the pharma industry. She founded the APHP Technology Transfer Office, creating over 75 health startups. She co-founded SparingVision and raised €130M. Now, she chairs PepKon’s Executive Committee and advises on R&D strategy.

Jean-Pascal TRANIÉ
Jean-Pascal TRANIÉ
Co-founder, President
A Polytechnique and ENA graduate, he is an entrepreneur and investor with CEO experience at Vivendi. Since 2017, he has focused on biotechnology, founding companies and launching Sorbonne Ventures. He was PepKon’s Managing Director and now serves as Chairman.
Read more
Jean-Pascal TRANIÉ
Jean-Pascal TRANIÉ
Co-founder, President
Access to PepKon's LinkedIn profils

A Polytechnique and ENA graduate, he is an entrepreneur and investor with CEO experience at Vivendi. Since 2017, he has focused on biotechnology, founding companies and launching Sorbonne Ventures. He was PepKon’s Managing Director and now serves as Chairman.

Patrick WEIL
Patrick WEIL
Co-Founder
Patrick Weil, a civil engineer and IAE Paris graduate, began his career in construction before founding the Prunay Group in 1993, specializing in insurance expertise. He led key successes, including the sales of Eurisk and Eurexo (to BlackFin). Now an entrepreneur and investor, he actively engages in biotech both operationally and financially.
Read more
Patrick WEIL
Patrick WEIL
Co-Founder
Access to PepKon's LinkedIn profils

Patrick Weil, a civil engineer and IAE Paris graduate, began his career in construction before founding the Prunay Group in 1993, specializing in insurance expertise. He led key successes, including the sales of Eurisk and Eurexo (to BlackFin). Now an entrepreneur and investor, he actively engages in biotech both operationally and financially.

Charles VILGRAIN
Charles VILGRAIN
Board Member & Investor
Charles graduated from ENSAIA and the executive MBA program at INSEAD. He began his career as an engineer before becoming a strategy consultant. He joined Caravelle in 2016 as Director of Investments and is now a Managing Partner.
Read more
Charles VILGRAIN
Charles VILGRAIN
Board Member & Investor
Access to PepKon's LinkedIn profils

Charles graduated from ENSAIA and the executive MBA program at INSEAD. He began his career as an engineer before becoming a strategy consultant. He joined Caravelle in 2016 as Director of Investments and is now a Managing Partner.

SAB, medical advisors

Véronique LEBLOND
Véronique LEBLOND
Hematologist
A leading hematologist with expertise in CLL and lymphomas, she led the Hematology Department at Pitié-Salpêtrière Hospital and contributed significantly to blood cancer research. Dr. Leblond, active in key hematology organizations, supports PepKon’s CLL work.
Read more
Véronique LEBLOND
Véronique LEBLOND
Hematologist
Access to PepKon's LinkedIn profils

A leading hematologist with expertise in CLL and lymphomas, she led the Hematology Department at Pitié-Salpêtrière Hospital and contributed significantly to blood cancer research. Dr. Leblond, active in key hematology organizations, supports PepKon’s CLL work.

Eric SOLARY
Eric SOLARY
Hematologist
A hematologist and professor at the University of Paris-Saclay, he is a former Director of Research at Gustave Roussy and founded Inserm units on cell death and cancer. His CMML research has resulted in 350+ publications. Dr. Solary, a 2018 Raymond-Rosen Prize recipient, collaborates with PepKon on CMML.
Read more
Eric SOLARY
Eric SOLARY
Hematologist
Access to PepKon's LinkedIn profils

A hematologist and professor at the University of Paris-Saclay, he is a former Director of Research at Gustave Roussy and founded Inserm units on cell death and cancer. His CMML research has resulted in 350+ publications. Dr. Solary, a 2018 Raymond-Rosen Prize recipient, collaborates with PepKon on CMML.

Jennifer R. BROWN
Jennifer R. BROWN
Hematologist-Oncologist
She holds an MD and PhD and is Director of the CLL Center at Dana-Farber Cancer Institute and Professor at Harvard Medical School. Renowned for her research on CLL genomics, which has led to over 150 publications, she is a leading CLL expert and a sought-after international speaker.
Read more
Jennifer R. BROWN
Jennifer R. BROWN
Hematologist-Oncologist
Access to PepKon's LinkedIn profils

She holds an MD and PhD and is Director of the CLL Center at Dana-Farber Cancer Institute and Professor at Harvard Medical School. Renowned for her research on CLL genomics, which has led to over 150 publications, she is a leading CLL expert and a sought-after international speaker.

Loïc YSEBAERT
Loïc YSEBAERT
Hematologist
He is a Senior Hematologist and Professor at the University of Toulouse, leading B-cell lymphoma studies and researching lymphoma immunotherapies and tumor resistance. A member of LYSA and FiLO-LLC, he collaborates with PepKon on CLL.
Read more
Loïc YSEBAERT
Loïc YSEBAERT
Hematologist
Access to PepKon's LinkedIn profils

He is a Senior Hematologist and Professor at the University of Toulouse, leading B-cell lymphoma studies and researching lymphoma immunotherapies and tumor resistance. A member of LYSA and FiLO-LLC, he collaborates with PepKon on CLL.